NCT01416402View on ClinicalTrials.gov

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
HyperuricemiaGout
Interventions
DRUG

Arhalofenate

400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks

DRUG

Febuxostat

80 mg once daily orally for 5 weeks

DRUG

Colchicine

Colchicine 0.6 mg daily as prophylaxis to prevent gout flares

Trial Locations (1)

66212

Overland Park

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY